Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Podcast The Why? Series Tools of the Trade View All Core Series Practice Questions
  • Tweetorials
  • About

Posts by Alyson Kaplan

Alyson Kaplan

Alyson Kaplan

Content Writer

@aly_kaplanMD
The Why? Series

Why do we use Lactulose and Rifaximin for Hepatic Encephalopathy?

Lactulose and Rifaximin (Xifaxan) are standards of care for the prevention of overt hepatic encephalopathy in patients with cirrhosis. Have you ever wondered why? Join us! First, if you want a...

Alyson Kaplan

Alyson Kaplan

July 6, 2021
The Why? Series

Why do we use living donors for liver transplantation?

In a very special installment of the Why Series, our adult and pediatric teams join forces to answer the question of how living donor liver transplantation came about in the United States. Read on!

Alyson Kaplan

Alyson Kaplan

Sindhu Pandurangi

Sindhu Pandurangi

March 14, 2021
The Why? Series

Why do we use the model for end-stage liver disease (MELD) score?: Part 2

In Part 1 of this series, we reviewed what came BEFORE the MELD score—Child-Turcotte-Pugh classification. We additionally discussed the history behind MELD, what is included in its calculation and why...

Alyson Kaplan

Alyson Kaplan

January 3, 2021
The Why? Series

Why do we use the model for end-stage liver disease (MELD) score?: Part 1

The Model for End-stage Liver Disease (or MELD) score is used to determine patient priority for liver transplantation. But have you ever wondered why? Let us review the history and the literature to...

Alyson Kaplan

Alyson Kaplan

November 17, 2020

Subscribe

Enter your email here and receive monthly newsletters with new LFN material.

Registration failed. Please try again later.

Thanks for signing up!

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2025 American Association for the Study of Liver Diseases